There will be no second phase one trial , safety across multiple rates of dosage was proven, one of these will be the dosage rate for future phase 2 trials
The clinical trial report concluded that single intravascular (IV) doses of ARG-007 at 0.03,
0.10, 0.20 and 0.30 mg/kg were safe and well tolerated with no dose related findings noted
for any of the evaluated safety parameters
AGN Media thread, page-130
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AGN (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
82.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $104.2M | |||
| Open | High | Low | Value | Volume |
| 82.0¢ | 83.0¢ | 81.0¢ | $79.25K | 97.02K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2287 | 82.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 82.5¢ | 5000 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| AGN (ASX) Chart |